Lead Product(s) : Nusinersen Sodium
Therapeutic Area : Genetic Disease
Study Phase : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
New Biomarker Data Support Potential Benefit of SPINRAZA in Infants
Details : Spinraza (nusinersen) is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.
Brand Name : Spinraza
Molecule Type : Large molecule
Upfront Cash : Not Applicable
March 06, 2024
Lead Product(s) : Nusinersen Sodium
Therapeutic Area : Genetic Disease
Highest Development Status : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Risdiplam
Therapeutic Area : Genetic Disease
Study Phase : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
CHMP Recommends Roche’s Evrysdi for Babies Under Two Months Old with Spinal Muscular Atrophy (SMA)
Details : Evrysdi (risdiplam) is a survival motor neuron 2 (SMN2) splicing modifier designed to treat SMA caused by mutations in chromosome 5q that lead to survival motor neuron (SMN) protein deficiency.
Brand Name : Evrysdi
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 21, 2023
Lead Product(s) : Risdiplam
Therapeutic Area : Genetic Disease
Highest Development Status : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Risdiplam
Therapeutic Area : Genetic Disease
Study Phase : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Evrysdi (risdiplam) is a survival motor neuron 2 (SMN2) splicing modifier designed to treat SMA caused by mutations in chromosome 5q that lead to survival motor neuron (SMN) protein deficiency.
Brand Name : Evrysdi
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 30, 2023
Lead Product(s) : Risdiplam
Therapeutic Area : Genetic Disease
Highest Development Status : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Lanadelumab
Therapeutic Area : Genetic Disease
Study Phase : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The observational Phase 4 EMPOWER study, evaluating real-world HAE attack rates before and after treatment with TAKHZYRO in patients with HAE types I and II, is ongoing. Full results of the EMPOWER study are expected to be published in 2024.
Brand Name : Takhzyro
Molecule Type : Large molecule
Upfront Cash : Not Applicable
February 28, 2022
Lead Product(s) : Lanadelumab
Therapeutic Area : Genetic Disease
Highest Development Status : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Idebenone
Therapeutic Area : Genetic Disease
Study Phase : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Santhera's Raxone® Meets Phase 4 Endpoint in Optic Neuropathy
Details : Raxone (idebenone) is an antioxidant benzoquinone, small molecule drug candidate which is indicated for the treatment of Leber’s Hereditary Optic Neuropathy.
Brand Name : Raxone
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 23, 2021
Lead Product(s) : Idebenone
Therapeutic Area : Genetic Disease
Highest Development Status : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Nusinersen Sodium
Therapeutic Area : Genetic Disease
Study Phase : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The RESPOND study aims to evaluate if Spinraza can benefit SMA patients who have experienced a ‘suboptimal’ response to Zolgensma (onasemnogene abeparvovec). It will be conducted at around 20 sites globally, with researchers aiming to enrol up to 60 ...
Brand Name : Spinraza
Molecule Type : Large molecule
Upfront Cash : Not Applicable
January 08, 2021
Lead Product(s) : Nusinersen Sodium
Therapeutic Area : Genetic Disease
Highest Development Status : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Recombinant coagulation factor IX
Therapeutic Area : Genetic Disease
Study Phase : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Medexus reached the 50% enrollment target in its Phase 4 clinical trial investigating IXINITY® as a prophylactic treatment for pediatric patients under 12 years of age with hemophilia B.
Brand Name : Ixinity
Molecule Type : Large molecule
Upfront Cash : Not Applicable
November 16, 2020
Lead Product(s) : Recombinant coagulation factor IX
Therapeutic Area : Genetic Disease
Highest Development Status : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Nusinersen Sodium
Therapeutic Area : Genetic Disease
Study Phase : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The RESPOND study will seek to understand if the proven efficacy of SPINRAZA and its continuous production of SMN protein may also benefit patients previously treated with gene therapy.
Brand Name : Spinraza
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 21, 2020
Lead Product(s) : Nusinersen Sodium
Therapeutic Area : Genetic Disease
Highest Development Status : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ivacaftor,Tezacaftor,Elexacaftor
Therapeutic Area : Genetic Disease
Study Phase : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The results of this study demonstrate that the triple combination provides significant additional benefit compared to existing CFTR modulator therapy for F/G and F/RF patients and supports the benefit of the medicine for patients with at least one F508de...
Brand Name : Trikafta
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 20, 2020
Lead Product(s) : Ivacaftor,Tezacaftor,Elexacaftor
Therapeutic Area : Genetic Disease
Highest Development Status : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ivacaftor,Tezacaftor,Elexacaftor
Therapeutic Area : Genetic Disease
Study Phase : Phase IV
Sponsor : Vertex Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Vertex Announces Expansion of Reimbursement Agreement With NHS England
Details : As part of the agreement with NHS England, Vertex has committed to submit ORKAMBI®, SYMKEVI® and KAFTRIO® to the National Institute for Health and Care Excellence (NICE) within an agreed upon timetable, allowing for a period of real-world data collect...
Brand Name : Kaftrio
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 30, 2020
Lead Product(s) : Ivacaftor,Tezacaftor,Elexacaftor
Therapeutic Area : Genetic Disease
Highest Development Status : Phase IV
Sponsor : Vertex Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?